|
|
Article: MacroGenics Licenses Therapeutic Target for Epstein-Barr Virus; Antibody Therapy to be Directed to Superantigen Protein.
- Article from:
- PR Newswire
- Article date:
- May 14, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ROCKVILLE, Md. -- MacroGenics, Inc. announced the licensing of a therapeutic target induced by Epstein-Barr virus (EBV), the cause of infectious mononucleosis ("mono") and certain lymphomas, from EBVax, Inc. and Tufts University.
Building on the findings of Dr. Brigitte Huber and Dr. David Thorley- Lawson, Professors of Pathology at Tufts University School of Medicine and Tufts-New England Medical Center and founders of EBVax, MacroGenics will launch a research program to identify treatments to reduce morbidity in patients suffering from the acute and chronic consequences of EBV infection.
Huber and Thorley-Lawson recently reported that EBV induces a ...
Related newspaper, magazine, and journal articles:
|
|
Article: Paulo F. Costa Joins MacroGenics Board of Directors.
PR Newswire;
June 23, 2009 ;
700+ words
... ... Md., June 23 /PRNewswire/ -- MacroGenics, Inc. announced today that Mr. Paulo ... Costa brings valuable expertise to the MacroGenics Board. "We are privileged to have Mr. Costa join MacroGenics' Board of Directors. As an established ...
|
|